Vascular endothelial growth factor gene polymorphisms and vitreous proteome changes in diabetic retinopathy.

about

Immune and inflammatory processes in obesity, insulin resistance, diabetes, and related cardiometabolic complications The role of pharmacogenetics and advances in gene therapy in the treatment of diabetic retinopathy.

P2860

Q34307131-389D1B8D-F4D4-41F4-BEE9-CD1F15A62207 Q38710512-50972645-C115-4DF8-A8B4-CE7BCF0A1DD3

P2860

Vascular endothelial growth factor gene polymorphisms and vitreous proteome changes in diabetic retinopathy.

Item

http://www.wikidata.org/entity/Q38153731

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Vascular endothelial growth fa ...... anges in diabetic retinopathy.

@en

type

Item

label

Vascular endothelial growth fa ...... anges in diabetic retinopathy.

@en

prefLabel

Vascular endothelial growth fa ...... anges in diabetic retinopathy.

@en

P1476

Vascular endothelial growth fa ...... anges in diabetic retinopathy.

@en

P2093

Jennifer K Sun

http://www.w3.org/2001/XMLSchema#string

Kelli H Dyer

http://www.w3.org/2001/XMLSchema#string

Paolo S Silva

http://www.w3.org/2001/XMLSchema#string

P2860

PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR

The role of genetics in susceptibility to diabetic retinopathy

Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation

Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edema

Vitreous and serum levels of vascular endothelial growth factor and platelet-derived growth factor and their correlation in patients with non-proliferative diabetic retinopathy and clinically significant macula oedema.

A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2.

Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema

Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins.

The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema.

Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.

P304

347-354

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/08820538.2013.825284

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

5-6

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258057246

http://www.w3.org/2001/XMLSchema#string

P698

24138044

http://www.w3.org/2001/XMLSchema#string

P921

endothelium

Vascular endothelial growth factor gene polymorphisms and vitreous proteome changes in diabetic retinopathy.

about

P2860

P2860

Vascular endothelial growth factor gene polymorphisms and vitreous proteome changes in diabetic retinopathy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P921